Table 1 Patient’s characteristic and PGL treatment

Sex (M : F)

71 : 68

44 : 39

25 : 26

2 : 3

Stage

I

94

I

42

I

48

I

4

(Lugano)

II

40

II

37

II

2

II

1

IV

5

IV

4

IV

1

Treatment

RT

50

RT

0

RT

49

RT

1

CT+RT

89

CT+RT

83

CT+RT

2

CT+RT

4

Rituximab

R+

40

R+

38

R+

1

R+

1

R-

99

R-

45

R-

50

R-

4

RT dose

40 Gy/20fr

35

30 Gy/15fr

23

40 Gy/20fr

2

40 Gy≧

89

40.5 Gy/27fr

45

30 Gy/20fr

24

40.5 Gy/27fr

2

40 Gy<

50

44 Gy/22fr

2

36 Gy/18fr

1

36 Gy/18fr

1

30 Gy/15fr

1

40 Gy/20fr

1

46 Gy/23fr

2

Observation length

mean 61.5 months

mean 62.7 months

mean 61.0 months

mean 46.9 months

(range)

(3.7–124.6)

(7.1–124.6)

(3.7–120.4)

(11.5–82.4)

5 year OS

92.0%

89.6%

97.7%

75.0%